Quoin Pharmaceuticals Ltd (QNRX) is a biotechnology company dedicated to innovating therapeutics targeting rare diseases and unmet medical needs. Leveraging advanced drug delivery technologies, QNRX aims to significantly improve the efficacy and safety profiles of existing treatments, establishing its foothold in the specialty pharmaceuticals arena. With a promising pipeline of therapies for critical health conditions, the company positions itself for significant clinical advancements and potential market transformations. Committed to delivering value to both patients and investors, Quoin actively pursues strategic collaborations and cutting-edge research initiatives to enhance its growth trajectory.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-17.36M |
| Operating Margin | 0.00% |
| Return on Equity | -231.20% |
| Return on Assets | -76.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.47 |
| Price-to-Book | 1.05 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $2.01M |
| Float | $1.63M |
| % Insiders | 2.63% |
| % Institutions | 52.50% |
Volatility is currently contracting
Quoin Pharmaceuticals (NASDAQ: QNRX) receives FDA IND clearance for a Phase 2 study of QRX003 in Peeling Skin Syndrome, with initiation expected in 2H 2026
ASHBURN, Va., June 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027 Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16 QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Supports Quoin's planned direct commercialization of QRX003 in Japan, one of its three core commercial territories Follows recent grant of Orphan Drug Designation to QRX003 by Japan's MHLW ASHBURN, Va., June 18, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved' or ‘Significantly Improved' from Baseline Assessment Across Key Clinical Endpoints All Six Patients Are Younger than 10 Years of Age, with the Youngest Being Just 6 Months Old Duration of Treatment To-Date Ranges from 3 Weeks to 15 Months No Treatment Related Adverse Events Reported for All Six Patients Additional Pediatric Patients Enrolling in Program in June and September Quoin Plans a Comprehensive Data Release, including from Ongoing Phase 2 Studies, in the Coming Months ASHBURN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
-Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval- -Follows Orphan Drug Designation, Pediatric Rare Disease Designation, and Fast Track Designation previously granted by the U.S. FDA, and Orphan Drug Designation previously granted by the European Medicines Agency- -Quoin is working closely with leading Japanese clinicians to refine clinical and regulatory pathway for approval- ASHBURN, Va., June 04, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
-First ever IND submission for this disease, which has no current treatment or cure- -Quoin plans Phase 2 study initiation in 2H 2026- -Submission supported by positive initial clinical data from Investigator-led pediatric study- -Second indication for QRX003, in addition to Netherton Syndrome- ASHBURN, Va., June 02, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
ASHBURN, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the first quarter ended March 31, 2026, before the market opens on Thursday, May 7, 2026.
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications.
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia Congenita Study Will be Led By Professor Edel O'Toole, Queen Mary University of London, Globally Recognized Leader in Pachyonychia Congenita Quoin Also Planning to Initiate Investigator Led Studies in Gorlin Syndrome and Tuberous Sclerosis Complex In addition to the Investigator Led Studies Company is Targeting to File Investigational New Drug Application to US Food and Drug Administration for QRX009 for an additional indication in Q3 2026 Quoin has Established Relationships With Key Advocacy Foundations including The PC Project and The Gorlin Syndrome Alliance as well as with Leading KOLs and Clinicians ASHBURN, Va.
